Selecting a Microbial Identification Service Provider for Biopharmaceutical QC

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-27

Quick Answer

Evaluate contract laboratories on method scope, reference database depth, and validation status before comparing price or turnaround time.
Require documented quality systems, audit access, and data integrity controls that match your regulatory submission needs.
Confirm the provider's identification methods and databases match your organism spectrum, because no single method identifies all microbes.

At a Glance

Evaluation Domain	What to Verify	Why It Matters
Method Scope	MALDI-TOF MS, 16S rRNA sequencing, Sanger sequencing, whole-genome sequencing, or biochemical panels	Different methods resolve different organism groups, and no single method covers all biopharmaceutical contaminants
Reference Database	Database version, number of species entries, and update frequency	Identification accuracy depends on the breadth and curation of the reference library
Quality Systems	ISO 17025 accreditation, GMP compliance, audit history, and corrective action records	Regulatory submissions require documented quality oversight and traceability
Data Integrity	Electronic records, audit trails, user access controls, and raw data retention	Data integrity failures can invalidate an entire release or stability study
Turnaround Time	Documented turnaround for routine and expedited testing	Delays affect batch release, deviation investigations, and stability programs
Sample Handling	Transport conditions, sample acceptance criteria, and rejection policies	Improper handling can produce false negatives or mixed cultures
Reporting	Report format, interpretation guidance, and raw data access	Reports must support your internal investigation and regulatory filing
Cost Structure	Per-sample pricing, method surcharges, and expedited fees	Cost transparency prevents budget overruns during contamination events

Scope of Microbial Identification in Biopharmaceutical Quality Control

Microbial identification in biopharmaceutical quality control serves a distinct purpose. The laboratory must determine whether a recovered organism is a known contaminant, a process-related organism, or a potential threat to product safety. The identification result feeds directly into deviation investigations, environmental monitoring assessments, and batch disposition decisions.

The scope of work for a contract laboratory includes several categories. The first category is routine environmental monitoring isolates. These are organisms recovered from cleanroom air, surfaces, and personnel monitoring. The second category is water system isolates. These organisms often come from purified water, water for injection, or process water systems. The third category is raw material and component isolates. These are organisms recovered from incoming materials. The fourth category is finished product isolates. These are organisms recovered from the product itself or from sterility testing.

The identification method must match the clinical question. A biochemical method may be sufficient for a common skin organism. A sequencing method may be necessary for a slow-growing organism or an organism that does not produce clear biochemical reactions. The contract laboratory must be able to explain which method is appropriate for each isolate and why.

The Role of the Contract Laboratory

A contract laboratory provides identification services when the biopharmaceutical manufacturer does not have the in-house capability or capacity. The contract laboratory must operate under a quality system that supports the manufacturer's regulatory obligations. The manufacturer remains responsible for the quality of the product, even when the testing is outsourced.

The contract laboratory must be able to demonstrate that its methods are validated and that its results are reliable. The manufacturer should review the laboratory's validation data, including accuracy, precision, and reproducibility. The manufacturer should also review the laboratory's participation in proficiency testing programs.

The contract laboratory must be able to provide raw data and metadata. The manufacturer must be able to audit the laboratory's records. The laboratory must be able to demonstrate that the data has not been altered or manipulated.

Core Principles of Microbial Identification Methods

Phenotypic Methods

Phenotypic methods identify organisms based on observable characteristics. These characteristics include colony morphology, Gram stain reaction, and biochemical reactions. The methods are often rapid and inexpensive. The methods are also limited by the organism's ability to grow and express the characteristics.

Biochemical methods use panels of substrates to produce a profile. The profile is compared to a database of known organisms. The accuracy of the method depends on the database and the quality of the inoculum. The method can misidentify organisms that are biochemically similar.

Phenotypic methods are useful for common organisms. The methods are less useful for organisms that are slow-growing, fastidious, or that do not produce clear biochemical reactions. The methods are also less useful for organisms that are closely related.

Genotypic Methods

Genotypic methods identify organisms based on their genetic material. The methods include 16S rRNA gene sequencing, whole-genome sequencing, and other molecular methods. The methods are more accurate than phenotypic methods for many organisms. The methods are also more expensive and require more time.

16S rRNA gene sequencing is a common method. The method amplifies and sequences the 16S ribosomal RNA gene. The sequence is compared to a database of known sequences. The method can identify organisms to the genus level and often to the species level. The method has limitations. The method cannot distinguish between some closely related species. The method also cannot identify organisms that have not been sequenced.

Whole-genome sequencing is a more comprehensive method. The method sequences the entire genome of the organism. The method can identify the organism to the species level and can also provide information about the organism's resistance genes and virulence factors. The method is expensive and requires specialized equipment and expertise.

Mass Spectrometry Methods

Matrix-assisted laser desorption ionization time-of-flight mass spectrometry is a rapid method for identifying organisms. The method uses a mass spectrometer to analyze the protein profile of the organism. The method is compared to a database of reference protein profiles. The method is rapid and can identify many organisms in a short time.

The method is limited by the database. The method cannot identify organisms that are not in the database. The method can also misidentify organisms that are closely related. The method is useful for routine identification of common organisms.

Method Selection

The selection of the identification method depends on the organism, the clinical question, and the laboratory's capabilities. The laboratory must be able to explain the method selection. The laboratory must also be able to explain the limitations of the method.

The laboratory must be able to provide the identification result with a confidence level. The confidence level is a measure of how well the result matches the database. The laboratory must be able to explain the confidence level and the limitations of the confidence level.

Evaluating the Provider's Technical Capabilities

Method Validation and Verification

The contract laboratory must be able to demonstrate that the identification methods are validated. The validation must include accuracy, precision, and reproducibility. The validation must also include the limits of detection and the limits of identification.

The laboratory must be able to provide the validation data. The data must include the number of organisms tested, the number of correct identifications, and the number of incorrect identifications. The data must also include the confidence levels for the identifications.

The laboratory must be able to verify the method for the specific use. The verification must include the organism types that are relevant to the biopharmaceutical laboratory. The verification must also include the sample types that are relevant to the biopharmaceutical laboratory.

Reference Database Quality

The reference database is the foundation of the identification method. The database must be comprehensive and current. The database must include the organisms that are relevant to the biopharmaceutical industry. The database must also include the organisms that are relevant to the clinical laboratory.

The laboratory must be able to describe the database. The laboratory must be able to state the number of organisms in the database. The laboratory must also be able to state the number of species in the database. The laboratory must be able to state the source of the database and the curation process.

The database must be updated regularly. The database must include new species and new strains. The database must also include the organisms that are emerging as contaminants in the biopharmaceutical industry.

Proficiency Testing

The contract laboratory must participate in proficiency testing programs. The proficiency testing program is a program in which the laboratory receives unknown organisms and must identify them. The laboratory must be able to demonstrate that the laboratory has passed the proficiency testing.

The laboratory must be able to provide the proficiency testing results. The results must include the number of organisms tested, the number of correct identifications, and the number of incorrect identifications. The results must also include the date of the proficiency testing.

The laboratory must be able to explain the proficiency testing program. The laboratory must be able to state the name of the program and the frequency of the testing.

Instrumentation and Equipment

The contract laboratory must have the appropriate instrumentation and equipment. The instrumentation must be calibrated and maintained. The instrumentation must be qualified for the intended use.

The laboratory must be able to provide the calibration and maintenance records. The records must include the dates of the calibration and maintenance. The records must also include the results of the calibration and maintenance.

The laboratory must be able to demonstrate that the instrumentation is appropriate for the method. The laboratory must be able to state the model of the instrument and the manufacturer. The laboratory must also be able to state the software version.

Quality Systems and Regulatory Compliance

Quality Management System

The contract laboratory must operate within a quality management system. The quality management system must be documented. The quality management system must include the policies, procedures, and records that govern the laboratory's operations.

The laboratory must be able to provide the quality management system documentation. The documentation must include the quality manual, the procedures, and the records. The laboratory must be able to demonstrate that the quality management system is implemented.

The laboratory must be able to demonstrate that the quality management system is effective. The laboratory must be able to demonstrate that the quality management system is reviewed regularly. The laboratory must also be able to demonstrate that the quality management system is improved.

Accreditation and Certification

The laboratory may be accredited to a standard. The accreditation is a formal recognition that the laboratory meets the requirements of the standard. The accreditation is granted by an accreditation body.

The laboratory may be certified to a standard. The certification is a formal recognition that the laboratory meets the requirements of the standard. The certification is granted by a certification body.

The laboratory must be able to provide the accreditation and certification certificates. The certificates must be current. The certificates must also be relevant to the scope of the testing.

The laboratory must be able to explain the accreditation and certification. The laboratory must be able to state the name of the accreditation body and the certification body. The laboratory must also be able to state the scope of the accreditation and certification.

Data Integrity

Data integrity is the extent to which data are complete, consistent, and accurate. Data integrity is a critical requirement for the biopharmaceutical industry. The laboratory must be able to demonstrate that the data are reliable.

The laboratory must be able to demonstrate that the data are attributable. The data must be traceable to the person who generated the data. The data must also be traceable to the instrument that generated the data.

The laboratory must be able to demonstrate that the data are legible. The data must be readable. The data must also be permanent.

The laboratory must be able to demonstrate that the data are contemporaneous. The data must be recorded at the time of the activity. The data must also be recorded in the order of the activity.

The laboratory must be able to demonstrate that the data are original. The data must be the original record. The data must also be the original observation.

The laboratory must be able to demonstrate that the data are accurate. The data must be free from errors. The data must also be free from omissions.

Audit Readiness

The laboratory must be ready for an audit. The audit is a formal review of the laboratory's operations. The audit may be conducted by the manufacturer, by a regulatory authority, or by a third party.

The laboratory must be able to provide the audit documentation. The documentation must include the quality management system, the procedures, and the records. The laboratory must also be able to provide the audit trail.

The laboratory must be able to demonstrate that the laboratory is ready for the audit. The laboratory must be able to demonstrate that the laboratory has a process for the audit. The laboratory must also be able to demonstrate that the laboratory has a process for the corrective action.

Practical Workflow for Selecting a Provider

Step 1: Define the Testing Requirements

The first step is to define the testing requirements. The requirements must include the organism types, the sample types, and the method types. The requirements must also include the turnaround time and the cost.

The manufacturer must consider the regulatory requirements. The manufacturer must also consider the clinical requirements. The manufacturer must also consider the business requirements.

Step 2: Identify the Candidate Providers

The second step is to identify the candidate providers. The providers must be able to meet the testing requirements. The providers must also be able to meet the quality requirements.

The manufacturer can identify the providers through a search. The manufacturer can also identify the providers through a referral. The manufacturer can also identify the providers through a professional organization.

Step 3: Request the Documentation

The third step is to request the documentation. The documentation must include the quality management system, the procedures, and the records. The documentation must also include the validation data and the proficiency testing results.

The manufacturer must review the documentation. The manufacturer must also verify the documentation. The manufacturer must also verify the accreditation and certification.

Step 4: Conduct the Audit

The fourth step is to conduct the audit. The audit must be conducted by a qualified auditor. The audit must be conducted at the laboratory's facility.

The audit must include the review of the quality management system. The audit must also include the review of the procedures. The audit must also include the review of the records.

The audit must include the observation of the laboratory's operations. The audit must also include the interview of the laboratory's personnel.

Step 5: Evaluate the Results

The fifth step is to evaluate the results. The manufacturer must evaluate the audit results. The manufacturer must also evaluate the documentation.

The manufacturer must evaluate the technical capabilities. The manufacturer must also evaluate the quality systems. The manufacturer must also evaluate the cost.

Step 6: Select the Provider

The sixth step is to select the provider. The manufacturer must select the provider that meets the requirements. The manufacturer must also select the provider that is the best value.

The manufacturer must document the selection. The manufacturer must also document the rationale for the selection.

Step 7: Establish the Agreement

The seventh step is to establish the agreement. The agreement must include the scope of the testing. The agreement must also include the turnaround time and the cost.

The agreement must include the quality requirements. The agreement must also include the data integrity requirements. The agreement must also include the audit requirements.

Records and Measurements

Records to Maintain

The manufacturer must maintain the records of the selection process. The records must include the testing requirements, the candidate providers, and the evaluation results. The records must also include the audit results and the selection rationale.

The manufacturer must maintain the records of the testing. The records must include the sample information, the identification results, and the interpretation. The records must also include the raw data and the metadata.

The manufacturer must maintain the records of the quality. The records must include the quality management system, the procedures, and the records. The records must also include the corrective action and the preventive action.

Measurements to Track

The manufacturer must track the measurements of the testing. The measurements must include the turnaround time, the accuracy, and the precision. The measurements must also include the cost.

The manufacturer must track the measurements of the quality. The measurements must include the number of deviations, the number of errors, and the number of corrective actions. The measurements must also include the number of audit findings.

The manufacturer must track the measurements of the provider. The measurements must include the provider's performance, the provider's responsiveness, and the provider's communication.

Common Failure Patterns

Failure Pattern 1: Incomplete Method Validation

A common failure is the incomplete validation of the identification method. The laboratory may not have validated the method for the specific organism types. The laboratory may also not have validated the method for the specific sample types.

The failure can result in the misidentification of the organism. The failure can also result in the failure to identify the organism. The failure can also result in the delay of the investigation.

The manufacturer must verify the validation data. The manufacturer must also verify the verification data. The manufacturer must also verify the proficiency testing data.

Failure Pattern 2: Inadequate Database Coverage

A common failure is the inadequate coverage of the reference database. The database may not include the organism types that are relevant to the biopharmaceutical industry. The database may also not include the organism types that are emerging.

The failure can result in the misidentification of the organism. The failure can also result in the failure to identify the organism. The failure can also result in the delay of the investigation.

The manufacturer must verify the database. The manufacturer must also verify the database updates. The manufacturer must also verify the database curation.

Failure Pattern 3: The Data Integrity Failure

A common failure is the data integrity failure. The laboratory may not have the audit trail. The laboratory may also not have the user access control. The laboratory may also not have the raw data retention.

The failure can result in the invalidation of the result. The failure can also result in the invalidation of the study. The failure can also result in the regulatory action.

The manufacturer must verify the data integrity. The manufacturer must also verify the audit trail. The manufacturer must also verify the user access control.

Failure Pattern 4: The Turnaround Time Failure

A common failure is the turnaround time failure. The laboratory may not be able to meet the turnaround time. The laboratory may also not be able to meet the turnaround time for the expedited testing.

The failure can result in the delay of the batch. The failure can also result in the delay of the investigation. The failure can also result in the delay of the stability study.

The manufacturer must verify the turnaround time. The manufacturer must also verify the turnaround time for the expedited testing. The manufacturer must also verify the turnaround time for the routine testing.

Failure Pattern 5: The Communication Failure

A common failure is the communication failure. The laboratory may not communicate the results in a timely manner. The laboratory may also not communicate the results in a clear manner.

The failure can result in the delay of the investigation. The failure can also result in the misinterpretation of the results. The failure can also result in the loss of the confidence.

The manufacturer must verify the communication. The manufacturer must also verify the communication plan. The manufacturer must also verify the communication process.

Biosafety and Containment Considerations

Risk Assessment

The laboratory must conduct a risk assessment for the identification methods. The risk assessment must consider the organism types, the sample types, and the methods. The risk assessment must also consider the laboratory's facilities and the laboratory's personnel.

The risk assessment must be documented. The risk assessment must also be reviewed. The risk assessment must also be updated.

The risk assessment must follow the principles of the biosafety in microbiological and biomedical laboratories. The risk assessment must consider the containment and the decontamination.

Containment

The laboratory must have the appropriate containment. The containment must be appropriate for the risk assessment. The containment must include the biological safety cabinets, the personal protective equipment, and the facility design.

The laboratory must have the appropriate decontamination. The decontamination must include the disinfection, the sterilization, and the waste disposal.

The laboratory must follow the principles of the biosafety in microbiological and biomedical laboratories. The laboratory must also follow the principles of the containment.

Personnel

The laboratory must have the appropriate personnel. The personnel must be trained. The personnel must also be competent.

The laboratory must have the appropriate training. The training must include the identification methods, the quality systems, and the biosafety. The training must also include the data integrity.

The laboratory must have the appropriate competency. The competency must be assessed. The competency must also be documented.

Antimicrobial Resistance Context

The Global Context

The identification of the organism is the first step in the management of the antimicrobial resistance. The identification of the organism is also the first step in the surveillance of the antimicrobial resistance.

The World Health Organization has defined the antimicrobial resistance as the resistance of a microorganism to an antimicrobial drug that was originally effective for the treatment of the infections. The antimicrobial resistance is a global public health concern.

The identification of the organism is the first step in the detection of the antimicrobial resistance. The identification of the organism is also the first step in the surveillance of the antimicrobial resistance.

The Biopharmaceutical Context

The biopharmaceutical industry has a role in the antimicrobial resistance. The industry must ensure that the products are free from the contamination. The industry must also ensure that the products are free from the antimicrobial resistance.

The laboratory must be able to identify the organism. The laboratory must also be able to detect the antimicrobial resistance. The laboratory must also be able to report the antimicrobial resistance.

Professional Escalation Criteria

When to Escalate

The manufacturer must escalate the issue when the issue is beyond the scope of the manufacturer's expertise. The manufacturer must also escalate the issue when the issue is beyond the scope of the laboratory's expertise.

The manufacturer must escalate the issue when the issue is a regulatory issue. The manufacturer must also escalate the issue when the issue is a safety issue. The manufacturer must also escalate the issue when the issue is a quality issue.

The manufacturer must escalate the issue when the issue is a data integrity issue. The manufacturer must also escalate the issue when the issue is a method issue. The manufacturer must also escalate the issue when the issue is a database issue.

How to Escalate

The manufacturer must escalate the issue to the appropriate person. The appropriate person may be the laboratory's quality manager. The appropriate person may also be the laboratory's technical director.

The manufacturer must escalate the issue to the appropriate authority. The appropriate authority may be the regulatory authority. The appropriate authority may also be the accreditation body.

The manufacturer must document the escalation. The manufacturer must also document the rationale for the escalation. The manufacturer must also document the outcome of the escalation.

Building a Weighted Scoring System for Provider Selection

A checklist approach to provider selection often fails because it treats every evaluation criterion as equally important. In practice, a laboratory that excels in turnaround time but has weak data integrity controls presents a different risk profile than one with the opposite pattern. A weighted scoring system forces the QC manager to assign relative importance to each evaluation domain before reviewing proposals, which reduces the influence of a single impressive sales presentation or a single concerning audit finding.

Defining the Scoring Categories

The scoring system should cover the same domains as the evaluation checklist but with explicit weights that reflect the manufacturer's regulatory exposure and operational needs. The categories are technical accuracy, data integrity, quality systems, turnaround time, cost, and communication. Each category receives a weight that sums to 100 percent across all categories.

Technical accuracy should receive the highest weight in most biopharmaceutical applications because a misidentification can lead to a wrong batch disposition decision. Data integrity should receive the second highest weight because a data integrity failure can invalidate an entire study or release decision. Regulatory compliance and quality systems should receive the next weights because they determine whether the provider can support a regulatory submission. Turnaround time and cost receive lower weights because they are operational factors that can be managed through the service agreement.

The QC manager must document the rationale for each weight assignment. The documentation should state the regulatory context, the product risk, and the operational constraints that drove the weighting decision. This documentation becomes part of the selection record and supports the audit trail for the outsourcing decision.

Assigning Scores to Each Criterion

Each criterion receives a score from one to five. A score of one means the provider does not meet the minimum requirement. A score of three means the provider meets the requirement with some limitations. A score of five means the provider exceeds the requirement with documented evidence.

For technical accuracy, the QC manager should score the provider based on the validation data, the proficiency testing results, and the reference database quality. A provider that has passed proficiency testing for the relevant organism groups and has a current database with documented curation receives a score of four or five. A provider that has limited validation data or a database that is not updated regularly receives a score of two or three. A provider that cannot provide validation data or proficiency testing results receives a score of one.

For data integrity, the QC manager should score the provider based on the audit trail, the user access controls, the raw data retention, and the electronic record system. A provider that has a validated electronic system with a complete audit trail and documented user access controls receives a score of four or five. A provider that uses paper records without a documented audit trail receives a score of two or three. A provider that cannot demonstrate any data integrity controls receives a score of one.

For regulatory compliance, the QC manager should score the provider based on the accreditation status, the certification status, and the audit history. A provider that has current accreditation for the relevant scope and a clean audit history receives a score of four or five. A provider that has accreditation but has recent audit findings receives a score of three. A provider that has no accreditation and no audit history receives a score of one.

Calculating the Weighted Total

The weighted total is the sum of the category score multiplied by the category weight. The QC manager should calculate the weighted total for each candidate provider and compare the results. The provider with the highest weighted total is not automatically the selected provider. The QC manager must also consider the qualitative factors that the scoring system does not capture.

The weighted total provides a structured comparison that supports the selection decision. The QC manager should document the calculation and the rationale for the final selection. The documentation should include the raw scores, the weighted scores, and the qualitative factors that influenced the final decision.

The scoring system should be applied consistently across all candidate providers. The QC manager should not adjust the weights or the scores after the evaluation has begun. If the QC manager discovers a new criterion that should be included, the QC manager should document the new criterion and apply it to all providers, beyond the provider that triggered the discovery.

Setting the Minimum Threshold

The QC manager should set a minimum threshold for the weighted total score. The threshold should reflect the minimum acceptable level of quality for the biopharmaceutical application. A provider that falls below the threshold should not be selected, regardless of the cost or the turnaround time.

The threshold should be set before the evaluation begins. The threshold should be documented in the selection plan. The threshold should be based on the regulatory requirements, the product risk, and the operational constraints.

The QC manager should also set a minimum threshold for each individual category. A provider that scores a one in any category should be disqualified, regardless of the total score. A provider that scores a two in data integrity should be disqualified for a product that is released based on the identification result.

Applying the Scoring System to the Audit

The scoring system should be applied during the audit, not after the audit. The QC manager should use the scoring system as a checklist during the audit. The QC manager should document the evidence for each score during the audit. The QC manager should also document the absence of evidence for each score.

The audit should include a review of the provider's quality management system, the provider's procedures, and the provider's records. The audit should also include an observation of the provider's operations and an interview of the provider's personnel. The audit should be conducted by a qualified auditor who has experience in biopharmaceutical quality control and microbial identification.

The audit should also include a review of the provider's proficiency testing results. The proficiency testing results should be reviewed for the relevant organism types. The proficiency testing results should also be reviewed for the relevant time period. The proficiency testing results should be reviewed for the relevant method types.

Recording the Scoring Results

The QC manager must record the scoring results in a format that supports the selection decision. The record should include the category weights, the category scores, the weighted scores, and the total score. The record should also include the evidence for each score and the rationale for each score.

The record should be maintained in the selection file. The record should be available for the audit. The record should also be available for the regulatory submission.

The record should be reviewed by the quality unit. The quality unit should verify that the scoring was applied consistently and that the selection decision is supported by the scoring results. The quality unit should also verify that the scoring results are consistent with the audit findings.

Using the Scoring System for Ongoing Monitoring

The scoring system should not be used only for the initial selection. The scoring system should also be used for the ongoing monitoring of the provider. The QC manager should re-score the provider on a regular basis, such as annually or after a significant event.

The re-scoring should be based on the provider's performance during the contract period. The re-scoring should include the turnaround time, the accuracy, the data integrity, and the communication. The re-scoring should also include the audit findings and the corrective action results.

The re-scoring should be documented and reviewed by the quality unit. The re-scoring should be used to decide whether to continue the contract, to renegotiate the contract, or to terminate the contract. The re-scoring should also be used to identify the areas where the provider needs to improve.

Common Scoring Errors

A common scoring error is the halo effect. The halo effect occurs when the QC manager gives a provider a high score in one category because the provider has a high score in another category. The halo effect can be reduced by scoring each category independently and by using the documented evidence for each category.

Another common scoring error is the recency effect. The recency effect occurs when the QC manager gives a provider a high score because of a recent positive interaction. The recency effect can be reduced by using the documented evidence for the entire evaluation period.

Another common scoring error is the anchoring effect. The anchoring effect occurs when the QC manager gives a provider a high score because the provider was the first provider evaluated. The anchoring effect can be reduced by evaluating all providers in a random order and by using the documented evidence for each provider.

The Scoring System and the Contract Agreement

The scoring system should be linked to the contract agreement. The contract agreement should include the performance metrics that are used in the scoring system. The contract agreement should also include the consequences for the failure to meet the performance metrics.

The contract agreement should include the turnaround time, the accuracy, the data integrity, and the communication. The contract agreement should also include the audit access and the corrective action requirements. The contract agreement should also include the termination clause for the failure to meet the performance metrics.

The contract agreement should be reviewed by the legal department and the quality unit. The contract agreement should be signed by the authorized representatives of both parties. The contract agreement should be retained in the contract file.

The Scoring System and the Regulatory Submission

The scoring system should be documented in the regulatory submission. The regulatory submission should include the selection process, the scoring system, and the scoring results. The regulatory submission should also include the rationale for the selection and the rationale for the scoring.

The regulatory submission should be reviewed by the regulatory affairs department. The regulatory submission should be consistent with the regulatory requirements. The regulatory submission should also be consistent with the quality management system.

The scoring system should be used to support the regulatory submission. The scoring system should demonstrate that the provider was selected based on the documented evidence and the documented rationale. The scoring system should also demonstrate that the provider was selected based on the quality and the data integrity.

The Scoring System and the Biosafety Context

The scoring system should also consider the biosafety context. The provider must have the appropriate containment and the appropriate decontamination procedures. The provider must also have the appropriate personnel training and the appropriate biosafety practices.

The scoring system should include a category for the biosafety. The biosafety category should be scored based on the provider's risk assessment, the containment, and the decontamination. The biosafety category should also be scored based on the provider's personnel training and the personnel competency.

The biosafety category should be weighted according to the risk of the organism types. The biosafety category should be weighted higher for the providers that handle the high-risk organisms. The biosafety category should also be weighted higher for the providers that handle the large volumes of the organisms.

The scoring system should be consistent with the biosafety principles in the Biosafety in Microbiological and Biomedical Laboratories. The scoring system should also be consistent with the professional microbiology practice in the American Society for Microbiology. The scoring system should also be consistent with the global antimicrobial resistance context in the World Health Organization.

Frequently Asked Questions

What is the difference between identification and characterization?

Identification is the determination of the identity of the organism. Characterization is the determination of the characteristics of the organism. Identification is the first step. Characterization is the second step.

What is the difference between a phenotypic method and a genotypic method?

A phenotypic method identifies the organism based on the observable characteristics. A genotypic method identifies the organism based on the genetic material. The genotypic method is more accurate than the phenotypic method.

What is the difference between a MALDI-TOF MS method and a 16S rRNA sequencing method?

A MALDI-TOF MS method identifies the organism based on the protein profile. A 16S rRNA sequencing method identifies the organism based on the genetic sequence. The MALDI-TOF MS method is faster than the 16S rRNA sequencing method.

What is the difference between a reference database and a sequence database?

A reference database is a database of the reference profiles. A sequence database is a database of the reference sequences. The reference database is used for the MALDI-TOF MS method. The sequence database is used for the 16S rRNA sequencing method.

What is the difference between a validation and a verification?

A validation is the demonstration that the method is suitable for the intended use. A verification is the demonstration that the method is suitable for the specific use. The validation is performed by the method developer. The verification is performed by the method user.

What is the difference between an audit and an inspection?

An audit is a formal examination of the laboratory's operations. An inspection is a formal examination of the laboratory's operations by a regulatory authority. The audit is conducted by the manufacturer or the customer. The inspection is conducted by the regulatory authority.

What is the difference between a corrective action and a preventive action?

A corrective action is an action to eliminate the cause of a nonconformity. A preventive action is an action to eliminate the cause of a potential nonconformity. The corrective action is performed after the nonconformity. The preventive action is performed before the nonconformity.

What is the difference between a deviation and an error?

A deviation is a departure from the procedure. An error is a mistake in the procedure. The deviation is a process issue. The error is a human issue.

Using the Evidence

Source	Best use in this topic	Important limitation
Biosafety in Microbiological and Biomedical Laboratories	official guidance	Check the linked page for current local requirements
Microbiology Resources	official guidance	Check the linked page for current local requirements
Antimicrobial Resistance	official guidance	Check the linked page for current local requirements

Related Diagnostic Guides

References and Further Reading

Biosafety in Microbiological and Biomedical Laboratories. CDC and NIH.
Microbiology Resources. American Society for Microbiology.
Antimicrobial Resistance. World Health Organization.
Bacteriological Analytical Manual. U.S. Food and Drug Administration.
Antimicrobial Susceptibility Testing. Clinical and Laboratory Standards Institute.
Culture Collections. American Type Culture Collection.
Laboratory Biosafety Manual. World Health Organization.
NCBI Literature Resources. National Center for Biotechnology Information.
EAACI Molecular Allergology User's Guide 2.0.. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2023.
Global burden of chronic respiratory diseases and risk factors, 1990-2019: an update from the Global Burden of Disease Study 2019.. EClinicalMedicine, 2023.
Global, regional, and national trends in routine childhood vaccination coverage from 1980 to 2023 with forecasts to 2030: a systematic analysis for the Global Burden of Disease Study 2023.. Lancet (London, England), 2025.

This article is educational and does not replace validated laboratory procedures, institutional biosafety review, manufacturer instructions, or professional interpretation.